Anesthesia, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy
Conditions
Brief summary
A combined approach of cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) represents a potential treatment option for patients diagnosed with primary or secondary gastrointestinal or gynaecological malignancies with peritoneal involvement. While the surgical phase of the operation macroscopically addresses the cancerous tissue, the HIPEC phase targets the microscopic tumour cells that remain after surgery (1). The surgical procedure known as SRC and HIPEC is one of the most complex surgical procedures, presenting numerous challenges for both the surgical and anaesthesia teams. The haemodynamic, haematological and metabolic changes that occur before, during and in the early postoperative period are associated with an increased risk of morbidity and mortality. It is therefore crucial for anaesthesia management to maintain normovolemia during surgery, compensate for hypothermia in the surgical phase and hyperthermia in the HIPEC phase, and maintain metabolic and haemodynamic balance throughout the entire procedure. The objective of this study was to retrospectively examine the anaesthesia management and clinical outcomes in patients who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in order to create literature information that can facilitate the early recognition and prevention of haemodynamic, haematological and metabolic problems that occur especially in the intraoperative and postoperative period.
Interventions
None listed
Sponsors
Sanliurfa Mehmet Akif Inan Education and Research Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* patients with primary or secondary gastrointestinal or gynecologic malignancies with peritoneal involvement. * Over 18 years of age
Exclusion criteria
* Over 80 years of age * those with heart, lung and liver diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anesthesia Management in Hyperthermic Intraperitoneal Chemotherapy | 01/01/2020 - 01/01/2024 | anaesthesia management in cytoreductive surgery and while hypertermic intraperitoneal chemotherapy |
| perioperative complications | during the operation | The potential complications associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be identified from the documented records. |
| fluid transfusion amounts | during the operation | The quantity of fluid transfusion administered to the patient during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be determined from documented records in millilitres. |
| blood replacements | during the operation | The quantity and type of blood and blood products transfused to the patient during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be determined from documented records in millilitres. |
| procedure times | during the operation | The duration of the surgical procedure applied to the patient during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be determined from the documents recorded in minutes. |
| 30-day mortality and morbidity | post-operative 30 days | The morbidity and mortality rate observed in the patient within 30 days of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be quantified as a percentage based on the documented records. |
Countries
Turkey (Türkiye)
Outcome results
None listed